INTRODUCTION
Cachexia is a common condition among 5 million Americans with CHF 6 and half a million Americans with ESRD requiring maintenance dialysis treatment to survive (1, 2) . Cardiovascular mortality accounts for most deaths in ESRD and CHF patients (3) . Whereas a decline in cardiovascular deaths has occurred in the general population, a similar trend has not been observed in CHF or dialysis patients (3, 4) .
Platelet reactivity plays a central role in the genesis of thrombosis and thromboembolic events, especially in atherosclerotic cardiovascular disease-the leading cause of death in ESRD and CHF patients (3) . To this end, antiplatelet therapy is used to decrease the occurrence of thromboembolic events (5) . Even relative thrombocytosis (ie, platelet counts .300 · 10 3 /lL) can be associated with the severity of cardiovascular disease in ESRD patient populations (6) . High ex vivo platelet reactivity appears to be associated with ischemic events (7) .
Renal cachexia, also known as PEW, is common in ESRD patients and is associated with poor outcomes (8, 9) . The close link between inflammation and PEW has led to the designation "malnutrition-inflammation-cachexia syndrome" (10) . MICS is a strong predictor of cardiovascular mortality in ESRD patients (8, 11) . However, even though many dialysis patients have preexisting cardiovascular disease and poor survival, it is still not clear why PEW, which is not a cardiovascular disease risk factor per se, is associated with higher cardiovascular mortality in this patient population. Discovering the pathophysiologic mechanisms underlying the PEW-death link can be a major step toward improving the clinical management of chronic diseases states with wasting syndrome.
In the general population, differences in platelet counts exist between men and women and between different ethnic groups (12) . Inflammatory cytokines are potent thrombopoietic factors (13) , and proinflammatory cytokines such as IL-6 and IL-11 enhance megakaryocyte maturation (14) . Cachexia, which is a proinflammatory condition per se, might lead to thrombocytosis and predispose to thromboembolic events and death, especially in the setting of preexisting cardiovascular disease. To date, no study has assessed the complex association between platelet count, MICS, and all-cause and cardiovascular mortality.
With the use of a large and contemporary cohort of maintenance hemodialysis patients from a single dialysis provider, we examined the hypothesis that a higher platelet count is associated with an increased risk of cardiovascular and all-cause mortality and that renal cachexia plays a role in this association.
SUBJECTS AND METHODS

Patients
We extracted, refined, and examined data from all individuals with ESRD who underwent hemodialysis treatment from July 2001 through June 2007 in 1 of 580 outpatient dialysis facilities of DaVita (DaVita Inc, before its acquisition of former Gambro dialysis facilities). The study was approved by all relevant Institutional Review Committees. Because of the large sample size, the anonymity of the patients studied, and the nonintrusive nature of the research, the study was exempt from the requirement of written consent. The first (baseline) studied quarter for each patient was the calendar quarter in which the patient's vintage was .90 d. We studied those hemodialysis patients whose platelet counts were measured, whose ages were between 16 and 99 y, who had started hemodialysis treatment in DaVita within the first 3 mo of therapy, and had a BMI (in kg/m 2 ) between 12 and 60.
Clinical and demographic measures
The creation of the national DaVita maintenance hemodialysis patient cohort was described previously (15) (16) (17) (18) (19) . To minimize measurement variability, all repeated measures for each patient during any given calendar quarter, ie, over a 13-wk interval, were averaged, and the summary estimates were used in all models. Dialysis vintage was defined as the duration of time between the first day of dialysis treatment and the first day that the patient entered the cohort. The presence or absence of diabetes at baseline and race-ethnicity were obtained directly from the DaVita database. Histories of tobacco smoking and preexisting comorbid conditions were obtained by linking the DaVita database to the Medical Evidence Form 2728 of the US Renal Data System (20) .
Cardiovascular death
The recorded causes of death were obtained from the US Renal Data System, and cardiovascular death was defined as death due to myocardial infarction, cardiac arrest, heart failure, cerebrovascular accident, and other cardiac causes.
Laboratory measures
Blood samples were drawn by using uniform techniques in all dialysis clinics and were transported to the DaVita Laboratory in Deland, FL, within 24 h. All laboratory values were measured by automated and standardized methods. Most laboratory values were measured monthly. Hemoglobin was measured at least monthly in all patients and weekly to biweekly in most patients. Glycated hemoglobin was usually measured semiannually or quarterly. The normalized protein equivalent of total nitrogen appearance (nPNA), also known as normalized protein catabolic rate (nPCR), was measured monthly as a measure of daily protein intake. Most blood samples were collected predialysis, except for postdialysis serum urea nitrogen to calculate urea kinetics. Platelet count was measured monthly as a part of the complete blood count. To create commensurate baseline values across diverse laboratory measures and to mitigate the measurement error, we averaged all weekly to monthly values into one single quarterly value per patient. Hence, the baseline platelet count used in this study was the averages of up to 3 monthly values per patient during the base calendar quarter. We divided platelet number into 7 a priori selected categories and defined the following ranges: ,150, 150 to ,200, 200 to ,250, 250 to ,300, 300 to ,350, 350 to ,400, and !400 · 10 3 /lL. For dichotomized analyses, we divided the platelet count into a moderate and a high range, ie, 150 to ,300 · 10 3 /lL as the reference and !300 · 10 3 /lL as relative thrombocytosis, respectively.
Epidemiologic and statistical methods
The descriptive statistics used include proportions and means (6 SD) as appropriate. We used ANOVA to compare patients with different platelet categories. Linear regression models were used to analyze the association between platelet number and different components of MICS. We built univariate and case-mix adjusted models (see below).
Survival analyses, including Cox proportional hazard regressions with baseline measures, were examined to determine whether the 6-y survival rates were associated with platelet counts. We also tested the linearity of all survival models using fractional polynomials and restricted cubic splines. For each analysis, 3 models were examined based on the level of multivariate adjustment: 1) Unadjusted model: included entry calendar quarter (quarter 1 through quarter 20) 2) Case-mix adjusted model: included the above factor plus age, sex, 10 preexisting comorbid states (ischemic heart disease, CHF, status after cardiac arrest, status after myocardial infarction, pericarditis, cardiac dysrhythmia, cerebrovascular events, peripheral vascular disease, chronic obstructive pulmonary disease, and cancer), categories of dialysis vintage (,6 mo, 6 mo to 2 y, 2-5 y, and !5 y), primary insurance (Medicare, Medicaid, private, and others), marital status (married, single, divorced, widowed, and other or unknown), the standardized mortality ratio of the dialysis clinic during entry quarter, dialysis dose as indicated by Kt/V (single pool), presence or absence of a dialysis catheter, and residual renal function during the entry quarter (ie, urinary urea clearance).
3) The MICS-adjusted models, which included all of the covariates in the case-mix model as well as 13 surrogates of nutritional status and inflammation, including BMI, the average dose of ESA, and 11 laboratory variables as surrogates of the nutritional state or inflammation, together also known as MICS, with known association with clinical outcomes in hemodialysis patients (21-23): 1) nPNA (nPCR) as an indicator of daily protein intake, 2) serum albumin, 3) serum TIBC, 4) serum ferritin, 5) serum creatinine, 6) serum phosphorus, 7) serum calcium, 8) serum bicarbonate, 9) peripheral white blood cell count, 10) lymphocyte percentage, and 11) iron saturation ratio.
Missing covariate data (,2% for most laboratory and demographic variables and ,18% for any of the 10 comorbid conditions) were imputed by the mean or median of the existing values, whichever was most appropriate. All descriptive and multivariate statistics were carried out with SAS (version 9.1; SAS Institute Inc).
RESULTS
The original 6-mo (July to December 2001) national database of all DaVita hemodialysis patients included 47,156 cumulative subjects. After the exclusion of those patients who did not continue hemodialysis treatment for .45 d, 41,093 hemodialysis patients remained for analysis, of whom 306 patients had missing core data, including platelet count or hemoglobin values. The final cohort included 40,787 hemodialysis patients, of whom 33,024 patients originated from the first calendar quarter data set and the rest from the subsequent calendar quarters. These patients were followed until death, loss to follow-up, or survival until 30 June 2007, as recorded in the DaVita databases. Of the 40,787 observed hemodialysis patients with a median follow-up time of 1066 d, there were 27,612 deaths (68%) and 11,051 cardiovascular deaths (27%). The mean age of the patients was 61 6 15 y, 46% were female, and 46% had diabetes mellitus ( Table 1) . The 3-mo averaged platelet count was 229 6 78 · 10 3 /lL. The demographic, clinical, and laboratory characteristics of the 40,797 hemodialysis patients in the 6-y DaVita cohort are compared between platelets categories in Table 1 . A higher platelet count was associated with a younger age, female sex, and a higher proportion of diabetes (Table 1) .
In unadjusted models, both an incrementally higher nPNA (nPCR) (Figure 1 , A) and higher serum creatinine concentration ( Figure 1B ) were associated with a lower platelet count. This association remained significant after adjustment for case-mix ( Figure 1 ). In unadjusted and case-mix adjusted models, incrementally higher blood hemoglobin concentrations were associated with a lower platelet count, whereas incrementally higher ESA doses were associated with a higher platelet count (OSM, Figure 1 ). Incrementally higher Kt/V values up to 2.2 were associated with a lower platelet count (OSM, Figure 2 ). A similar trend was found in for the association between serum albumin and platelet count (OSM, Figure 3 ).
To identify the potential risk factors that may link relative thrombocytosis (ie, platelet count !300 · 10 3 /lL) to mortality, we performed logistic regression analyses. After case-mix adjustment, the risk of relative thrombocytosis was also associated with younger age, lower serum albumin and creatinine concentrations, lower lymphocyte percentages, and lower Kt/V and nPNA (nPCR) values as a surrogate of lower dietary protein intake ( Table 2) .
The association of a priori selected platelet count categories with the risk of cardiovascular and all-cause death via Cox regression models is shown in Figure 2 , A and B. Compared with patients with a platelet count between 150 and ,200 · 10 3 /lL (reference), the unadjusted odds of cardiovascular death in 40,797 hemodialysis patients with platelet counts between 300 and ,350, 350 and ,400, and ! 400 · 10 3 /lL were 7%, 15%, and 25% higher (P , 0.05), respectively. These U-shaped associations persisted after case-mix adjustment; however, further adjustment for MICS abolished, in some ranges even reversed, the association. Similar associations were observed with allcause mortality (Figure 2A ). We found similar results when we examined the association between platelet count (restricted to 150 to ,500 · 10 3 /lL) and mortality association using fractional polynomials and restricted cubic splines (OSM; Figure 4 ). Every 100 · 10 3 /lL increase in platelet count was associated with a 13% higher risk of cardiovascular mortality (HR: 1.13; 95% CI: 1.09, 1.16; P , 0.001) and a 14% higher risk of allcause mortality (HR: 1.14; 95% CI: 1.12, 1.16; P , 0.001) in our case-mix model ( Table 3) . Further adjustment for MICS reversed the association, both in cardiovascular mortality (HR: 0.95; 95% CI: 0.92, 0.98; P = 0.003) and in all-cause mortality (HR: 0.96; 95% CI: 0.94, 0.98; P , 0.001).
Similar results were found when the mortality-predictability of a high platelet count (150-300 · 10 3 /lL compared with !300 · 10 3 /lL) was examined across different subgroups of patients (see forest plots in Figure 3 , A and B). The unadjusted cardiovascular death HRs were above unity in almost all examined subgroups, which indicated a higher risk of poor cardiovascular outcomes with higher platelet counts. These associations persisted after case-mix adjustment in almost all examined subgroups; however, further adjustment for MICS abolished and in some ranges even reversed the association. Similar associations were observed with all-cause mortality ( Figure 3B ).
DISCUSSION
In a contemporary cohort of 40,787 adult hemodialysis patients, we found that higher platelet counts were associated with correlates of renal cachexia, including lower serum albumin and creatinine concentrations, lower blood hemoglobin and lymphocyte percentages, lower nPNA (nPCR) values (reflecting lower dietary protein intake), lower Kt/V values, and higher erythropoietin doses. Compared with patients with a platelet count between 150 and 200 · 10 3 /lL as the reference, the all-cause and cardiovascular death risk were incrementally higher across higher platelet count categories. Whereas the cardiovascular death risk of a higher platelet count persisted after case-mix adjustment, further adjustment for surrogates of renal cachexia nullified or even reversed the associations. These findings may have important clinical implications, because they advance the hypothesis that a higher platelet count is a predictor of cardiovascular death risk in hemodialysis patients, but that its association with cardiovascular and all-cause mortality is almost fully accounted for by the renal cachexia ( Figure 4) .
In our study, we found that a higher platelet count was associated with markers of MICS, including a lower dietary protein intake, a lower dialysis dose, and a higher ESA dose. To the best of our knowledge only a few studies have examined platelet counts, MICS, and outcomes in ESRD populations (24, 25) . In this study we found that a higher ESA dose and a lower hemoglobin concentration were associated with a higher platelet concentration. Streja et al (25) found that a high ESA dose can cause relative thrombocytosis by promoting iron depletion in hemodialysis patients. In the same way, in a prospective, doubleblind, randomized, placebo-controlled clinical trial, including 244 hemodialysis patients, Kaupke et al (26) showed that administration of a relatively high dose of recombinant erythropoietin significantly increased the platelet count. These observations suggest a potential explanation for the dissociation of higher ESA dose and poor outcomes.
We found that a higher platelet count was associated with lower serum albumin and creatinine concentrations, a lower lymphocyte count, and a lower nPNA (nPCR) value as a surrogate of lower dietary protein intake. A similar trend was found with Kt/V, in that the lower Kt/V was associated with a higher platelet count. Serum albumin is a marker of both PEW and inflammation in hemodialysis patients (27) ; low nPNA (nPCR) is also related to malnutrition and poor outcome (28) , and serum creatinine is a surrogate of muscle mass in hemodialysis patients (18, 29, 30) . A low lymphocyte percentage is also a malnutrition marker (31) . Our findings suggest that a high platelet count correlates with MICS. A potential explanation for these associations is the modulation by inflammatory cytokines. Platelets are generated from fragmentation of the cytoplasm of megakaryocytes, which are the byproduct of proliferation and differentiation of colony-forming unit megakaryocytes (32) . Megakaryopoiesis is regulated by inflammation factors such as IL-6, IL-11, and leukemia inhibitor factor, which predominantly support megakaryocyte maturation (33) . Similarly, through the actions of IL-6 and other cytokines, inflammation, which is common in ESRD patients, can cause reactive thrombocytosis (34) . Previous studies have clearly shown elevated concentration of inflammatory cytokines in hemodialysis patients with renal cachexia, also known as MICS (8, 35, 36) . We also found that relative thrombocytosis is a predictor of both all-cause and cardiovascular death risk in hemodialysis patients, but that its mortality predictability is fully accounted for by the surrogates of renal cachexia. Platelet reactivity plays a central role in thromboembolic events, especially in the setting of atherosclerotic cardiovascular disease, which is the leading cause of death in ESRD patients (3) . In the early 1970s, Evans et al (37) described the platelet function abnormalities in uremic patients. Moreover, the high platelet reactivity determined in diabetic patients with coronary artery disease is associated with a higher risk of adverse cardiovascular events (38) . To this end, antiplatelet therapy is used to decrease the occurrence of . Case-mix adjusted model: adjusted for entry calendar quarter plus age, sex, 10 preexisting comorbid states, categories of dialysis vintage, primary insurance, marital status, the standardized mortality ratio of the dialysis clinic during entry quarter, dialysis dose as indicated by Kt/V (single pool), the presence or absence of a dialysis catheter, and residual renal function during the entry quarter (ie, urinary urea clearance). Case-mix-and malnutrition-inflammation cachexia syndrome (MICS)-adjusted model: adjusted for all of the covariates in the case-mix model plus BMI, the average dose of erythropoietin stimulating agent, normalized protein equivalent of total nitrogen appearance-also known as normalized protein catabolic rate -as an indicator of daily protein intake, serum albumin, serum total-iron-binding capacity, serum ferritin, serum creatinine, serum phosphorus, serum calcium, serum bicarbonate, peripheral white blood cell count, lymphocyte percentage, and iron saturation ratio. thromboembolic events (5) , even though, Chan et al (39) recently found no benefit associated with use of antiplatelet therapy in this population, and perhaps higher mortality, which may be related to confounding by indication. In peritoneal dialysis patients with diabetes, thrombocytosis is associated with the severity of cardiovascular disease (6) . In the current study we analyzed platelet counts rather than the level of platelet function. Cardiovascular mortality may still be independently associated with platelet function. Previous studies found that high ex vivo platelet reactivity is associated with ischemic events (7) ; however, this has not been studied in patients with ESRD. Furthermore, studies are needed to answer this question. Although surrogates of renal cachexia are consistently associated with mortality in ESRD patients (8, 11) , it is not clear through which mechanisms renal cachexia and death are related. da Silva et al (40) reported that platelet aggregation induced by collagen is impaired in patients with well-nourished chronic renal failure relative to malnourished patients and control subjects. Plasma L-arginine concentrations are reduced in chronic renal failure patients and are even lower in malnourished patients. The absence of the adaptive response in the L-arginine-nitric oxide pathway in platelets from malnourished chronic renal failure patients may account for the enhanced occurrence of thromboembolic events in these patients (40) . Moreover, reduced plasma L-arginine and nitric oxide production and elevated cytokine concentrations are associated with increased aggregability of platelets taken from malnourished uremic patients (41) . In our unadjusted and casemix adjusted model, a higher platelet count was associated with higher all-cause and cardiovascular mortality. Malnourished chronic renal failure patients had a higher platelet count and increased aggregability of platelets, which can enhance thromboembolic events-the leading cause of death in ESRD patients (3) . After adjustment for MICS, the association between platelet number and all-cause and cardiovascular mortality did not exist. These findings can advance the hypothesis that renal cachexia increases mortality via increasing platelet count and activity. Our hypothesis of a platelet-mortality association in ESRD patients and its link to wasting syndrome is shown in Figure 4 . In the MICS-adjusted model, we accounted for the intermediary factors in the pathway between renal cachexia and thrombocytosis, resulting in abolishment of the mortality predictability of high platelet count. This hypothesis needs to be examined in randomized controlled trials.
Our study was limited by its observational nature. Like all observational studies, this analysis cannot distinguish direct causation from confounding. Another limitation of our study was that no antiplatelet medication was included in our analysis. However, Chan et al (39) found no benefit associated with the use of antiplatelet therapy in this population, and perhaps higher mortality, which may be related to confounding by indication. Additionally, missing medications, no platelet function, and residual measured or unmeasured confounders could have accounted for some or all of the relations. Moreover, we did not have data for other platelet variables, which may relate to the activation status of the platelets, such as impedance compared with optical measurements, immunological measurements, platelet clumping, or other biomarkers of platelet activation (42, 43) . An additional weakness of our study was that we had only one platelet measurement; therefore, we were not able to analyze the association of outcome and platelet number changes over time. An important strength of our study was its large sample size, which allowed us to account for important covariates in the multivariate analyses and to examine specific associations, thus providing points of focus in future studies. To the best of our knowledge, our study was the first to examine the association of platelet count and all-cause and cardiovascular survival in hemodialysis patients.
In conclusion, a higher platelet count is associated with surrogates of renal cachexia and cardiovascular mortality in hemodialysis patients. However, the association of platelet count with all-cause and cardiovascular mortality is accounted for by indexes of renal cachexia. Whereas the hypothesis that renal cachexia increases mortality via increasing platelet counts needs to be examined in additional studies, the findings do not necessarily imply a causal relation.
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